Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

The drug used to treat Parkinson's disease, most notably levodopa (SINEMET) , is also prescribed for MSA individuals. However, the efficacy of such medications varies greatly among the affected ...

a protein implicated in neurodegenerative diseases like Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Improved technologies for small molecules ...

Learn more about the MSA treatment landscape @ Drugs for Multiple System Atrophy Treatment The drug used to treat Parkinson's disease, most notably levodopa (SINEMET), is also prescribed for MSA ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

The symptoms of MSA are wide-ranging and include muscle control problems, similar to those of Parkinson's disease. Many different functions of the body can be affected, and symptoms including ...